Development of a simple antioxidant screening assay using human skin fibroblasts.
The purpose of this study was to develop a simple antioxidant screening assay for quantifying the protective effects of antioxidant enzymes, inhibitors and scavengers against extracellularly generated oxygen species on human skin fibroblast cytotoxicity. Different in vitro oxidative stresses have been studied: xanthine oxidase-hypoxanthine, flavin mononucleotide-NADH, and hydrogen peroxide. Cytotoxicity and protection were evaluated by two procedures: evaluation of the living cells using a colorimetric method (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide MTT), and ability of the viable cells to adherate and proliferate. Hypoxanthine-xanthine oxidase and H2O2 induced a dose dependent cytotoxicity only when we considered the delayed toxicity. The influence of the cell density was also investigated. The delayed toxicity was higher when cell density increased. One hundred percent protection against free radical cytotoxicity induced by the three systems were obtained with catalase (500 U/ml). When the oxidative stress used was H2O2 90-96% protection was obtained with deferoxamine an iron chelating agent that prevents iron catalysed radical reactions. Using the colorimetric method no significant protection was obtained when SOD was added before and during the stresses. Using the fibroblasts ability to proliferate SOD (10-150 micrograms/ml) reduced xanthine oxidase (20 U/l)-hypoxanthine (0.10-0.30 mM) or H2O2 (1-6 mM) cytotoxicity by 15-20%. SOD did not act as antioxidant when the applied stress was mediated by flavin. In this study we showed a paradoxical effect and the cytotoxicity of flavin-NADH system increased when we added SOD to the cell medium. This simple and reliable antioxidant screening assay required no costly or radioactive equipment.
Richard
M J
MJ
Laboratoire de Brochimie C, Chru Albert Michallon, Grenoble, France.
Guiraud
P
P
Monjo
A M
AM
Favier
A
A
D002374:Catalase / Q000494:pharmacology*; D003676:Deferoxamine / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D005347:Fibroblasts / Q000187:drug effects / Q000201:enzymology; D005486:Flavin Mononucleotide / Q000037:antagonists & inhibitors; D005609:Free Radicals; D006801:Humans; D006861:Hydrogen Peroxide / Q000037:antagonists & inhibitors; D009243:NAD / Q000037:antagonists & inhibitors; D010100:Oxygen / Q000378:metabolism*; D012867:Skin / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D013482:Superoxide Dismutase / Q000494:pharmacology*; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
D005609:Free Radicals; D009243:NAD; D005486:Flavin Mononucleotide; D006861:Hydrogen Peroxide; D002374:Catalase; D013482:Superoxide Dismutase; D014969:Xanthine Oxidase; D003676:Deferoxamine; D010100:Oxygen